New and emerging therapies for inflammatory bowel disease.
作者信息
Danese Silvio
机构信息
Head of the IBD Center Department of Gastroenterology Istituto Clinico Humanitas Milan, Italy.
出版信息
Gastroenterol Hepatol (N Y). 2012 Dec;8(12):844-6.
Abstract
摘要
相似文献
1
New and emerging therapies for inflammatory bowel disease.炎症性肠病的新型及新兴疗法
Gastroenterol Hepatol (N Y). 2012 Dec;8(12):844-6.
2
New developments in the treatment of inflammatory bowel disease.炎症性肠病治疗的新进展
Expert Opin Investig Drugs. 2002 Mar;11(3):365-85. doi: 10.1517/13543784.11.3.365.
3
Immunotherapy in inflammatory bowel disease: Novel and emerging treatments.炎症性肠病的免疫疗法：新出现的治疗方法。
Hum Vaccin Immunother. 2018;14(11):2597-2611. doi: 10.1080/21645515.2018.1461297. Epub 2018 May 22.
4
Molecular pathogenesis of inflammatory bowel disease: relevance for novel therapies.炎症性肠病的分子发病机制：与新型疗法的相关性。
Per Med. 2008 Nov;5(6):609-626. doi: 10.2217/17410541.5.6.609.
5
The impact of pregnancy on biologic therapies for the treatment of inflammatory bowel disease.妊娠对炎症性肠病生物治疗的影响。
Best Pract Res Clin Gastroenterol. 2020 Feb-Apr;44-45:101670. doi: 10.1016/j.bpg.2020.101670. Epub 2020 Mar 13.
6
Immunopathogenesis of inflammatory bowel disease and mechanisms of biological therapies.炎症性肠病的免疫发病机制及生物治疗机制
Scand J Gastroenterol. 2018 Apr;53(4):379-389. doi: 10.1080/00365521.2018.1447597. Epub 2018 Mar 9.
7
Use of alternative and complementary therapies by inflammatory bowel disease patients in an Italian tertiary referral centre.意大利一家三级转诊中心炎症性肠病患者使用替代疗法和补充疗法的情况。
Dig Liver Dis. 2007 Jun;39(6):524-9. doi: 10.1016/j.dld.2007.03.001. Epub 2007 Apr 11.
8
Safety considerations with biologics and new inflammatory bowel disease therapies.生物制剂和新型炎症性肠病治疗的安全性考虑。
Curr Opin Gastroenterol. 2020 Jul;36(4):257-264. doi: 10.1097/MOG.0000000000000607.
9
When combination therapy isn't working: emerging therapies for the management of inflammatory bowel disease.当联合治疗无效时：炎症性肠病管理的新兴疗法。
World J Gastroenterol. 2014 Feb 7;20(5):1139-46. doi: 10.3748/wjg.v20.i5.1139.
10
An update on irritable bowel syndrome: from diagnosis to emerging therapies.肠易激综合征的最新进展：从诊断到新兴治疗方法。
Curr Opin Gastroenterol. 2011 Jan;27(1):72-8. doi: 10.1097/MOG.0b013e3283414065.
本文引用的文献
1
Ustekinumab induction and maintenance therapy in refractory Crohn's disease.乌司奴单抗诱导和维持治疗难治性克罗恩病。
N Engl J Med. 2012 Oct 18;367(16):1519-28. doi: 10.1056/NEJMoa1203572.
2
Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.托法替布，一种口服的 Janus 激酶抑制剂，用于治疗活动期溃疡性结肠炎。
N Engl J Med. 2012 Aug 16;367(7):616-24. doi: 10.1056/NEJMoa1112168.
3
Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study.维得利珠单抗治疗活动期溃疡性结肠炎的随机对照 2 期剂量范围研究。
Inflamm Bowel Dis. 2012 Aug;18(8):1470-9. doi: 10.1002/ibd.21896. Epub 2011 Dec 6.
4
New therapies for inflammatory bowel disease: from the bench to the bedside.炎症性肠病的新疗法：从实验室到临床。
Gut. 2012 Jun;61(6):918-32. doi: 10.1136/gutjnl-2011-300904. Epub 2011 Nov 23.
5
Biological therapy for ulcerative colitis: what is after anti-TNF.溃疡性结肠炎的生物治疗：抗 TNF 之后是什么。
Curr Drug Targets. 2011 Sep;12(10):1433-9. doi: 10.2174/138945011796818225.
Zotero 插件